ADDICTIONS NURSING · ADVANCED PRACTICE
CARN-AP EXAM 2026/2027 | 208 QUESTIONS| WITH 100% VERIFIED ANSWERS!!
2026/2027
Complete Blueprint Coverage
A+
A+ 8 100%
QUESTIONS VERIFIED EXAM DOMAINS COVERED RATIONALES INCLUDED
CATEGORIES
Opioid Use Disorder Assessment and Pharmacotherapy
Alcohol Use Disorder and Withdrawal Management
Stimulant Cannabis Tobacco and Other Substance Use Disorders
Co-occurring Psychiatric and Medical Conditions
Screening Assessment and Motivational Interventions
Medications for Addiction Treatment and Harm Reduction
Special Populations Pregnancy Adolescents and Older Adults
Professional Issues Ethics Confidentiality and Practice Leadership
STUVIAACTUALEXAM
,OPIOID USE DISORDER ASSESSMENT AND PHARMACOTHERAPY
Q1
An APRN is evaluating a patient with opioid use disorder in the context of buprenorphine initiation after MAT Act. The clinical setting is an outpatient
addiction practice and the patient has no immediate life-threatening complication. What is the priority evidence-based action?
A. Immediately stop all opioid agonist therapy without a transition plan
B. Apply current clinical guidelines specific to this situation while monitoring safety and engaging the patient in shared decision-making
C. Refer exclusively to residential treatment and offer no office-based options
D. Increase concurrent benzodiazepines to cover any withdrawal symptoms
Correct Answer: B
Rationale:
After the MAT Act any DEA-registered Schedule III prescriber may initiate buprenorphine for OUD without an X-waiver.
Q2
An APRN is evaluating a patient with opioid use disorder in the context of perioperative pain in patient on buprenorphine. The clinical setting is an
outpatient addiction practice and the patient has no immediate life-threatening complication. What is the priority evidence-based action?
A. Immediately stop all opioid agonist therapy without a transition plan
B. Apply current clinical guidelines specific to this situation while monitoring safety and engaging the patient in shared decision-making
C. Refer exclusively to residential treatment and offer no office-based options
D. Increase concurrent benzodiazepines to cover any withdrawal symptoms
Correct Answer: B
Rationale:
Continue buprenorphine and add multimodal analgesia including short-acting full agonists as needed; abrupt cessation risks relapse.
Q3
An APRN is evaluating a patient with opioid use disorder in the context of fentanyl and precipitated withdrawal risk. The clinical setting is an outpatient
addiction practice and the patient has no immediate life-threatening complication. What is the priority evidence-based action?
A. Immediately stop all opioid agonist therapy without a transition plan
B. Apply current clinical guidelines specific to this situation while monitoring safety and engaging the patient in shared decision-making
C. Refer exclusively to residential treatment and offer no office-based options
D. Increase concurrent benzodiazepines to cover any withdrawal symptoms
Correct Answer: C
Rationale:
Micro-induction or delayed induction is preferred when residual fentanyl raises precipitated-withdrawal risk.
Q4
An APRN is evaluating a patient with opioid use disorder in the context of OUD pharmacotherapy in pregnancy. The clinical setting is an outpatient
addiction practice and the patient has no immediate life-threatening complication. What is the priority evidence-based action?
A. Immediately stop all opioid agonist therapy without a transition plan
B. Apply current clinical guidelines specific to this situation while monitoring safety and engaging the patient in shared decision-making
C. Refer exclusively to residential treatment and offer no office-based options
D. Increase concurrent benzodiazepines to cover any withdrawal symptoms
Correct Answer: B
Rationale:
Methadone or buprenorphine maintenance improves maternal and neonatal outcomes versus withdrawal alone.
Q5
An APRN is evaluating a patient with opioid use disorder in the context of methadone QT prolongation. The clinical setting is an outpatient addiction
practice and the patient has no immediate life-threatening complication. What is the priority evidence-based action?
A. Immediately stop all opioid agonist therapy without a transition plan
B. Apply current clinical guidelines specific to this situation while monitoring safety and engaging the patient in shared decision-making
C. Refer exclusively to residential treatment and offer no office-based options
D. Increase concurrent benzodiazepines to cover any withdrawal symptoms
Correct Answer: B
Rationale:
Evaluate reversible causes, consider dose reduction or transition to buprenorphine, and obtain cardiology input.
Q6
An APRN is evaluating a patient with opioid use disorder in the context of transition to extended-release injectable buprenorphine. The clinical setting is
an outpatient addiction practice and the patient has no immediate life-threatening complication. What is the priority evidence-based action?
A. Immediately stop all opioid agonist therapy without a transition plan
B. Apply current clinical guidelines specific to this situation while monitoring safety and engaging the patient in shared decision-making
C. Refer exclusively to residential treatment and offer no office-based options
D. Increase concurrent benzodiazepines to cover any withdrawal symptoms
Correct Answer: B
Rationale:
Stable sublingual buprenorphine for the labeled period is required before the first subcutaneous injection.
,CARN-AP EXAM 2026/2027 | 208 QUESTIONS| WITH 100% VERIFIED ANSWERS!! 2026/2027
Q7
An APRN is evaluating a patient with opioid use disorder in the context of initial methadone dosing limits. The clinical setting is an outpatient addiction
practice and the patient has no immediate life-threatening complication. What is the priority evidence-based action?
A. Immediately stop all opioid agonist therapy without a transition plan
B. Apply current clinical guidelines specific to this situation while monitoring safety and engaging the patient in shared decision-making
C. Refer exclusively to residential treatment and offer no office-based options
D. Increase concurrent benzodiazepines to cover any withdrawal symptoms
Correct Answer: B
Rationale:
Day-1 methadone dose is limited to 30-40 mg with careful titration because of delayed respiratory depression risk.
Q8
An APRN is evaluating a patient with opioid use disorder in the context of CYP3A4 inducers and buprenorphine. The clinical setting is an outpatient
addiction practice and the patient has no immediate life-threatening complication. What is the priority evidence-based action?
A. Immediately stop all opioid agonist therapy without a transition plan
B. Apply current clinical guidelines specific to this situation while monitoring safety and engaging the patient in shared decision-making
C. Refer exclusively to residential treatment and offer no office-based options
D. Increase concurrent benzodiazepines to cover any withdrawal symptoms
Correct Answer: A
Rationale:
Strong inducers can lower buprenorphine levels; prefer non-inducing anti-emetics and monitor for withdrawal.
Q9
An APRN is evaluating a patient with opioid use disorder in the context of overdose risk after abstinence. The clinical setting is an outpatient addiction
practice and the patient has no immediate life-threatening complication. What is the priority evidence-based action?
A. Immediately stop all opioid agonist therapy without a transition plan
B. Apply current clinical guidelines specific to this situation while monitoring safety and engaging the patient in shared decision-making
C. Refer exclusively to residential treatment and offer no office-based options
D. Increase concurrent benzodiazepines to cover any withdrawal symptoms
Correct Answer: B
Rationale:
Loss of tolerance after abstinence markedly elevates overdose risk if prior doses are resumed.
Q10
An APRN is evaluating a patient with opioid use disorder in the context of COWS interpretation for induction. The clinical setting is an outpatient
addiction practice and the patient has no immediate life-threatening complication. What is the priority evidence-based action?
A. Immediately stop all opioid agonist therapy without a transition plan
B. Apply current clinical guidelines specific to this situation while monitoring safety and engaging the patient in shared decision-making
C. Refer exclusively to residential treatment and offer no office-based options
D. Increase concurrent benzodiazepines to cover any withdrawal symptoms
Correct Answer: B
Rationale:
Mild-to-moderate COWS scores support induction timing to minimize precipitated withdrawal.
Q11
An APRN is evaluating a patient with opioid use disorder in the context of hepatic impairment and buprenorphine. The clinical setting is an outpatient
addiction practice and the patient has no immediate life-threatening complication. What is the priority evidence-based action?
A. Immediately stop all opioid agonist therapy without a transition plan
B. Apply current clinical guidelines specific to this situation while monitoring safety and engaging the patient in shared decision-making
C. Refer exclusively to residential treatment and offer no office-based options
D. Increase concurrent benzodiazepines to cover any withdrawal symptoms
Correct Answer: B
Rationale:
Dose adjustment and closer monitoring are required in moderate-to-severe hepatic impairment.
Q12
An APRN is evaluating a patient with opioid use disorder in the context of reinduction after relapse. The clinical setting is an outpatient addiction
practice and the patient has no immediate life-threatening complication. What is the priority evidence-based action?
A. Immediately stop all opioid agonist therapy without a transition plan
B. Apply current clinical guidelines specific to this situation while monitoring safety and engaging the patient in shared decision-making
C. Refer exclusively to residential treatment and offer no office-based options
D. Increase concurrent benzodiazepines to cover any withdrawal symptoms
Correct Answer: B
Rationale:
Reassess withdrawal severity and restart induction using current guidelines rather than resuming the previous high dose.
, CARN-AP EXAM 2026/2027 | 208 QUESTIONS| WITH 100% VERIFIED ANSWERS!! 2026/2027
Q13
An APRN is evaluating a patient with opioid use disorder in the context of methadone to buprenorphine transfer. The clinical setting is an outpatient
addiction practice and the patient has no immediate life-threatening complication. What is the priority evidence-based action?
A. Immediately stop all opioid agonist therapy without a transition plan
B. Apply current clinical guidelines specific to this situation while monitoring safety and engaging the patient in shared decision-making
C. Refer exclusively to residential treatment and offer no office-based options
D. Increase concurrent benzodiazepines to cover any withdrawal symptoms
Correct Answer: B
Rationale:
Careful taper of methadone and observation for withdrawal before buprenorphine reduces precipitated withdrawal risk.
Q14
An APRN is evaluating a patient with opioid use disorder in the context of LAI buprenorphine and elective surgery. The clinical setting is an outpatient
addiction practice and the patient has no immediate life-threatening complication. What is the priority evidence-based action?
A. Immediately stop all opioid agonist therapy without a transition plan
B. Apply current clinical guidelines specific to this situation while monitoring safety and engaging the patient in shared decision-making
C. Refer exclusively to residential treatment and offer no office-based options
D. Increase concurrent benzodiazepines to cover any withdrawal symptoms
Correct Answer: B
Rationale:
Coordinate with anesthesia; supplemental analgesia and possible supplemental sublingual doses may be needed.
Q15
An APRN is evaluating a patient with opioid use disorder in the context of patient with OUD and acute hepatitis. The clinical setting is an outpatient
addiction practice and the patient has no immediate life-threatening complication. What is the priority evidence-based action?
A. Immediately stop all opioid agonist therapy without a transition plan
B. Apply current clinical guidelines specific to this situation while monitoring safety and engaging the patient in shared decision-making
C. Refer exclusively to residential treatment and offer no office-based options
D. Increase concurrent benzodiazepines to cover any withdrawal symptoms
Correct Answer: B
Rationale:
Assess severity, avoid hepatotoxic agents when possible, and continue or adjust MAT based on clinical status.
Q16
An APRN is evaluating a patient with opioid use disorder in the context of urine drug screen interpretation on buprenorphine. The clinical setting is an
outpatient addiction practice and the patient has no immediate life-threatening complication. What is the priority evidence-based action?
A. Immediately stop all opioid agonist therapy without a transition plan
B. Apply current clinical guidelines specific to this situation while monitoring safety and engaging the patient in shared decision-making
C. Refer exclusively to residential treatment and offer no office-based options
D. Increase concurrent benzodiazepines to cover any withdrawal symptoms
Correct Answer: B
Rationale:
Buprenorphine and norbuprenorphine should be present; unexpected substances require non-judgmental discussion and possible dose or treatment adjustment.
Q17
An APRN is evaluating a patient with opioid use disorder in the context of patient requests only naltrexone after recent opioid use. The clinical setting is
an outpatient addiction practice and the patient has no immediate life-threatening complication. What is the priority evidence-based action?
A. Immediately stop all opioid agonist therapy without a transition plan
B. Apply current clinical guidelines specific to this situation while monitoring safety and engaging the patient in shared decision-making
C. Refer exclusively to residential treatment and offer no office-based options
D. Increase concurrent benzodiazepines to cover any withdrawal symptoms
Correct Answer: B
Rationale:
Full opioid abstinence is required before naltrexone; offer bridge strategies or alternative MAT if abstinence is not yet achieved.
Q18
An APRN is evaluating a patient with opioid use disorder in the context of office-based vs OTP for high-risk patient. The clinical setting is an outpatient
addiction practice and the patient has no immediate life-threatening complication. What is the priority evidence-based action?
A. Immediately stop all opioid agonist therapy without a transition plan
B. Apply current clinical guidelines specific to this situation while monitoring safety and engaging the patient in shared decision-making
C. Refer exclusively to residential treatment and offer no office-based options
D. Increase concurrent benzodiazepines to cover any withdrawal symptoms
Correct Answer: B
Rationale:
Severity, psychosocial needs, and patient preference guide level of care; high-risk patients may benefit from OTP structure.
CARN-AP EXAM 2026/2027 | 208 QUESTIONS| WITH 100% VERIFIED ANSWERS!!
2026/2027
Complete Blueprint Coverage
A+
A+ 8 100%
QUESTIONS VERIFIED EXAM DOMAINS COVERED RATIONALES INCLUDED
CATEGORIES
Opioid Use Disorder Assessment and Pharmacotherapy
Alcohol Use Disorder and Withdrawal Management
Stimulant Cannabis Tobacco and Other Substance Use Disorders
Co-occurring Psychiatric and Medical Conditions
Screening Assessment and Motivational Interventions
Medications for Addiction Treatment and Harm Reduction
Special Populations Pregnancy Adolescents and Older Adults
Professional Issues Ethics Confidentiality and Practice Leadership
STUVIAACTUALEXAM
,OPIOID USE DISORDER ASSESSMENT AND PHARMACOTHERAPY
Q1
An APRN is evaluating a patient with opioid use disorder in the context of buprenorphine initiation after MAT Act. The clinical setting is an outpatient
addiction practice and the patient has no immediate life-threatening complication. What is the priority evidence-based action?
A. Immediately stop all opioid agonist therapy without a transition plan
B. Apply current clinical guidelines specific to this situation while monitoring safety and engaging the patient in shared decision-making
C. Refer exclusively to residential treatment and offer no office-based options
D. Increase concurrent benzodiazepines to cover any withdrawal symptoms
Correct Answer: B
Rationale:
After the MAT Act any DEA-registered Schedule III prescriber may initiate buprenorphine for OUD without an X-waiver.
Q2
An APRN is evaluating a patient with opioid use disorder in the context of perioperative pain in patient on buprenorphine. The clinical setting is an
outpatient addiction practice and the patient has no immediate life-threatening complication. What is the priority evidence-based action?
A. Immediately stop all opioid agonist therapy without a transition plan
B. Apply current clinical guidelines specific to this situation while monitoring safety and engaging the patient in shared decision-making
C. Refer exclusively to residential treatment and offer no office-based options
D. Increase concurrent benzodiazepines to cover any withdrawal symptoms
Correct Answer: B
Rationale:
Continue buprenorphine and add multimodal analgesia including short-acting full agonists as needed; abrupt cessation risks relapse.
Q3
An APRN is evaluating a patient with opioid use disorder in the context of fentanyl and precipitated withdrawal risk. The clinical setting is an outpatient
addiction practice and the patient has no immediate life-threatening complication. What is the priority evidence-based action?
A. Immediately stop all opioid agonist therapy without a transition plan
B. Apply current clinical guidelines specific to this situation while monitoring safety and engaging the patient in shared decision-making
C. Refer exclusively to residential treatment and offer no office-based options
D. Increase concurrent benzodiazepines to cover any withdrawal symptoms
Correct Answer: C
Rationale:
Micro-induction or delayed induction is preferred when residual fentanyl raises precipitated-withdrawal risk.
Q4
An APRN is evaluating a patient with opioid use disorder in the context of OUD pharmacotherapy in pregnancy. The clinical setting is an outpatient
addiction practice and the patient has no immediate life-threatening complication. What is the priority evidence-based action?
A. Immediately stop all opioid agonist therapy without a transition plan
B. Apply current clinical guidelines specific to this situation while monitoring safety and engaging the patient in shared decision-making
C. Refer exclusively to residential treatment and offer no office-based options
D. Increase concurrent benzodiazepines to cover any withdrawal symptoms
Correct Answer: B
Rationale:
Methadone or buprenorphine maintenance improves maternal and neonatal outcomes versus withdrawal alone.
Q5
An APRN is evaluating a patient with opioid use disorder in the context of methadone QT prolongation. The clinical setting is an outpatient addiction
practice and the patient has no immediate life-threatening complication. What is the priority evidence-based action?
A. Immediately stop all opioid agonist therapy without a transition plan
B. Apply current clinical guidelines specific to this situation while monitoring safety and engaging the patient in shared decision-making
C. Refer exclusively to residential treatment and offer no office-based options
D. Increase concurrent benzodiazepines to cover any withdrawal symptoms
Correct Answer: B
Rationale:
Evaluate reversible causes, consider dose reduction or transition to buprenorphine, and obtain cardiology input.
Q6
An APRN is evaluating a patient with opioid use disorder in the context of transition to extended-release injectable buprenorphine. The clinical setting is
an outpatient addiction practice and the patient has no immediate life-threatening complication. What is the priority evidence-based action?
A. Immediately stop all opioid agonist therapy without a transition plan
B. Apply current clinical guidelines specific to this situation while monitoring safety and engaging the patient in shared decision-making
C. Refer exclusively to residential treatment and offer no office-based options
D. Increase concurrent benzodiazepines to cover any withdrawal symptoms
Correct Answer: B
Rationale:
Stable sublingual buprenorphine for the labeled period is required before the first subcutaneous injection.
,CARN-AP EXAM 2026/2027 | 208 QUESTIONS| WITH 100% VERIFIED ANSWERS!! 2026/2027
Q7
An APRN is evaluating a patient with opioid use disorder in the context of initial methadone dosing limits. The clinical setting is an outpatient addiction
practice and the patient has no immediate life-threatening complication. What is the priority evidence-based action?
A. Immediately stop all opioid agonist therapy without a transition plan
B. Apply current clinical guidelines specific to this situation while monitoring safety and engaging the patient in shared decision-making
C. Refer exclusively to residential treatment and offer no office-based options
D. Increase concurrent benzodiazepines to cover any withdrawal symptoms
Correct Answer: B
Rationale:
Day-1 methadone dose is limited to 30-40 mg with careful titration because of delayed respiratory depression risk.
Q8
An APRN is evaluating a patient with opioid use disorder in the context of CYP3A4 inducers and buprenorphine. The clinical setting is an outpatient
addiction practice and the patient has no immediate life-threatening complication. What is the priority evidence-based action?
A. Immediately stop all opioid agonist therapy without a transition plan
B. Apply current clinical guidelines specific to this situation while monitoring safety and engaging the patient in shared decision-making
C. Refer exclusively to residential treatment and offer no office-based options
D. Increase concurrent benzodiazepines to cover any withdrawal symptoms
Correct Answer: A
Rationale:
Strong inducers can lower buprenorphine levels; prefer non-inducing anti-emetics and monitor for withdrawal.
Q9
An APRN is evaluating a patient with opioid use disorder in the context of overdose risk after abstinence. The clinical setting is an outpatient addiction
practice and the patient has no immediate life-threatening complication. What is the priority evidence-based action?
A. Immediately stop all opioid agonist therapy without a transition plan
B. Apply current clinical guidelines specific to this situation while monitoring safety and engaging the patient in shared decision-making
C. Refer exclusively to residential treatment and offer no office-based options
D. Increase concurrent benzodiazepines to cover any withdrawal symptoms
Correct Answer: B
Rationale:
Loss of tolerance after abstinence markedly elevates overdose risk if prior doses are resumed.
Q10
An APRN is evaluating a patient with opioid use disorder in the context of COWS interpretation for induction. The clinical setting is an outpatient
addiction practice and the patient has no immediate life-threatening complication. What is the priority evidence-based action?
A. Immediately stop all opioid agonist therapy without a transition plan
B. Apply current clinical guidelines specific to this situation while monitoring safety and engaging the patient in shared decision-making
C. Refer exclusively to residential treatment and offer no office-based options
D. Increase concurrent benzodiazepines to cover any withdrawal symptoms
Correct Answer: B
Rationale:
Mild-to-moderate COWS scores support induction timing to minimize precipitated withdrawal.
Q11
An APRN is evaluating a patient with opioid use disorder in the context of hepatic impairment and buprenorphine. The clinical setting is an outpatient
addiction practice and the patient has no immediate life-threatening complication. What is the priority evidence-based action?
A. Immediately stop all opioid agonist therapy without a transition plan
B. Apply current clinical guidelines specific to this situation while monitoring safety and engaging the patient in shared decision-making
C. Refer exclusively to residential treatment and offer no office-based options
D. Increase concurrent benzodiazepines to cover any withdrawal symptoms
Correct Answer: B
Rationale:
Dose adjustment and closer monitoring are required in moderate-to-severe hepatic impairment.
Q12
An APRN is evaluating a patient with opioid use disorder in the context of reinduction after relapse. The clinical setting is an outpatient addiction
practice and the patient has no immediate life-threatening complication. What is the priority evidence-based action?
A. Immediately stop all opioid agonist therapy without a transition plan
B. Apply current clinical guidelines specific to this situation while monitoring safety and engaging the patient in shared decision-making
C. Refer exclusively to residential treatment and offer no office-based options
D. Increase concurrent benzodiazepines to cover any withdrawal symptoms
Correct Answer: B
Rationale:
Reassess withdrawal severity and restart induction using current guidelines rather than resuming the previous high dose.
, CARN-AP EXAM 2026/2027 | 208 QUESTIONS| WITH 100% VERIFIED ANSWERS!! 2026/2027
Q13
An APRN is evaluating a patient with opioid use disorder in the context of methadone to buprenorphine transfer. The clinical setting is an outpatient
addiction practice and the patient has no immediate life-threatening complication. What is the priority evidence-based action?
A. Immediately stop all opioid agonist therapy without a transition plan
B. Apply current clinical guidelines specific to this situation while monitoring safety and engaging the patient in shared decision-making
C. Refer exclusively to residential treatment and offer no office-based options
D. Increase concurrent benzodiazepines to cover any withdrawal symptoms
Correct Answer: B
Rationale:
Careful taper of methadone and observation for withdrawal before buprenorphine reduces precipitated withdrawal risk.
Q14
An APRN is evaluating a patient with opioid use disorder in the context of LAI buprenorphine and elective surgery. The clinical setting is an outpatient
addiction practice and the patient has no immediate life-threatening complication. What is the priority evidence-based action?
A. Immediately stop all opioid agonist therapy without a transition plan
B. Apply current clinical guidelines specific to this situation while monitoring safety and engaging the patient in shared decision-making
C. Refer exclusively to residential treatment and offer no office-based options
D. Increase concurrent benzodiazepines to cover any withdrawal symptoms
Correct Answer: B
Rationale:
Coordinate with anesthesia; supplemental analgesia and possible supplemental sublingual doses may be needed.
Q15
An APRN is evaluating a patient with opioid use disorder in the context of patient with OUD and acute hepatitis. The clinical setting is an outpatient
addiction practice and the patient has no immediate life-threatening complication. What is the priority evidence-based action?
A. Immediately stop all opioid agonist therapy without a transition plan
B. Apply current clinical guidelines specific to this situation while monitoring safety and engaging the patient in shared decision-making
C. Refer exclusively to residential treatment and offer no office-based options
D. Increase concurrent benzodiazepines to cover any withdrawal symptoms
Correct Answer: B
Rationale:
Assess severity, avoid hepatotoxic agents when possible, and continue or adjust MAT based on clinical status.
Q16
An APRN is evaluating a patient with opioid use disorder in the context of urine drug screen interpretation on buprenorphine. The clinical setting is an
outpatient addiction practice and the patient has no immediate life-threatening complication. What is the priority evidence-based action?
A. Immediately stop all opioid agonist therapy without a transition plan
B. Apply current clinical guidelines specific to this situation while monitoring safety and engaging the patient in shared decision-making
C. Refer exclusively to residential treatment and offer no office-based options
D. Increase concurrent benzodiazepines to cover any withdrawal symptoms
Correct Answer: B
Rationale:
Buprenorphine and norbuprenorphine should be present; unexpected substances require non-judgmental discussion and possible dose or treatment adjustment.
Q17
An APRN is evaluating a patient with opioid use disorder in the context of patient requests only naltrexone after recent opioid use. The clinical setting is
an outpatient addiction practice and the patient has no immediate life-threatening complication. What is the priority evidence-based action?
A. Immediately stop all opioid agonist therapy without a transition plan
B. Apply current clinical guidelines specific to this situation while monitoring safety and engaging the patient in shared decision-making
C. Refer exclusively to residential treatment and offer no office-based options
D. Increase concurrent benzodiazepines to cover any withdrawal symptoms
Correct Answer: B
Rationale:
Full opioid abstinence is required before naltrexone; offer bridge strategies or alternative MAT if abstinence is not yet achieved.
Q18
An APRN is evaluating a patient with opioid use disorder in the context of office-based vs OTP for high-risk patient. The clinical setting is an outpatient
addiction practice and the patient has no immediate life-threatening complication. What is the priority evidence-based action?
A. Immediately stop all opioid agonist therapy without a transition plan
B. Apply current clinical guidelines specific to this situation while monitoring safety and engaging the patient in shared decision-making
C. Refer exclusively to residential treatment and offer no office-based options
D. Increase concurrent benzodiazepines to cover any withdrawal symptoms
Correct Answer: B
Rationale:
Severity, psychosocial needs, and patient preference guide level of care; high-risk patients may benefit from OTP structure.
